Physician
Retinal Diagnostic Center a Medical Corporation
Retinal Diagnostic Center a Medical Corporation was paid $5.05M by Medicaid between Jan 2018 and Nov 2024, across 29 billing codes. Its largest line is J2777, Injection, faricimab-svoa, 0.1 mg — 24% of everything it billed.
33Billing provider infoRETINAL DIAGNOSTIC CENTER A MEDICAL CORPORATION
CAMPBELL, CA 95008
CAMPBELL, CA 95008
33aNPI1518030568assigned 11/16/2006
33bProvider typeOphthalmology Physician
28Total paid$5.05M
24GClaims93,552
24DCodes billed29
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Ophthalmology Physician providers in California
Rank by total paid#12 of 759
Median peer was paid$35K
This provider vs. median143×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 10,989 | $320K | |
| 2019 | 11,354 | $359K | |
| 2020 | 9,590 | $348K | |
| 2021 | 12,574 | $498K | |
| 2022 | 14,388 | $661K | |
| 2023 | 18,404 | $1.31M | |
| 2024incomplete | 16,253 | $1.55M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J2777 | Injection, faricimab-svoa, 0.1 mg | 24% | 1,395 | 1,306 | $1.22M |
| 67028 | Intravitreal injection of a pharmacologic agent | 21% | 16,644 | 15,489 | $1.07M |
| J0178 | Injection, aflibercept, 1 mg | 11% | 776 | 730 | $562K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | 8.4% | 10,120 | 9,804 | $426K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 7.7% | 13,452 | 13,334 | $391K |
| 92134 | 7.7% | 26,700 | 25,808 | $391K | |
| J9035 | Injection, bevacizumab, 10 mg | 5.7% | 7,603 | 7,099 | $289K |
| J2778 | Injection, ranibizumab, 0.1 mg | 4.6% | 849 | 819 | $233K |
| 92250 | 3.1% | 7,177 | 7,061 | $154K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 2.9% | 2,116 | 2,106 | $148K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.3% | 804 | 801 | $66K |
| 76512 | <1% | 3,236 | 2,657 | $49K |
17 more codes
| 67228 | <1% | 107 | $27K | |
| 92235 | <1% | 420 | $25K | |
| 92226 | <1% | 105 | $423.49 | |
| J7999 | Compounded drug, not otherwise classified | <1% | 59 | $273.20 |
| 92225 | <1% | 22 | $137.12 | |
| G9744 | Patient not eligible due to active diagnosis of hypertension | 0% | 312 | $0.00 |
| 2026F | 0% | 322 | $0.00 | |
| 2022F | 0% | 324 | $0.00 | |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 57 | $0.00 |
| G9974 | Dilated macular exam performed, including documentation of the presence or absence of macular thickening or geographic atrophy or hemorrhage and the level of macular degeneration severity | 0% | 13 | $0.00 |
| 2024F | 0% | 322 | $0.00 | |
| G8482 | Influenza immunization administered or previously received | 0% | 12 | $0.00 |
| 5010F | 0% | 16 | $0.00 | |
| 1036F | 0% | 394 | $0.00 | |
| 4177F | 0% | 50 | $0.00 | |
| G9903 | Patient screened for tobacco use and identified as a tobacco non-user | 0% | 130 | $0.00 |
| 2019F | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKELLEY, TIM (OFFICE MANAGER)